Prospect Financial Services LLC Takes Position in ARK Genomic Revolution ETF (BATS:ARKG)

Prospect Financial Services LLC acquired a new stake in ARK Genomic Revolution ETF (BATS:ARKG) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,123 shares of the company’s stock, valued at approximately $431,000.

Other hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in shares of ARK Genomic Revolution ETF by 112.8% in the fourth quarter. BNP Paribas Financial Markets now owns 1,156,701 shares of the company’s stock valued at $37,951,000 after buying an additional 613,063 shares during the period. SG Americas Securities LLC raised its holdings in ARK Genomic Revolution ETF by 835.6% during the 4th quarter. SG Americas Securities LLC now owns 213,059 shares of the company’s stock worth $6,990,000 after purchasing an additional 190,287 shares during the last quarter. Del Sette Capital Management LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 4th quarter worth approximately $3,253,000. Tower Research Capital LLC TRC bought a new stake in shares of ARK Genomic Revolution ETF in the 3rd quarter valued at $2,007,000. Finally, International Assets Investment Management LLC increased its position in shares of ARK Genomic Revolution ETF by 120.1% during the fourth quarter. International Assets Investment Management LLC now owns 107,617 shares of the company’s stock worth $3,280,000 after buying an additional 58,715 shares during the period.

ARK Genomic Revolution ETF Stock Down 2.8 %

BATS ARKG traded down $0.73 during mid-day trading on Friday, reaching $25.05. 1,820,064 shares of the stock were exchanged. The company has a 50 day moving average of $25.27 and a 200 day moving average of $28.41.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.